Skip to main content

Table 1 Characteristics of AD patients and controls

From: Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

Subject details

Controls (n = 22)

AD patients (n = 37)

p value

Gender (F/M), no (%)

10(45)/12(55)

19(53)/18(47)

0.6

Age, years (mean ± SD)

69.2 ± 8.0

70.51 ± 7.5

0.54

MMSE score (median IQR)

29.00(26.50-29.00)

22.00(18.00-25.00

<0.0001

APOE ε4 positive (%)

33 %

67 %

0.0002

Plasma CRP (mg/L), median (IQR)

2.095 (0.8425 – 4.7535) n = 16

1.020 (0.6500 – 1.295) n = 25

0.0543

CSF Biomarkers

Aβ1-42 (pg/ml), median (IQR)

978.5(821.8-1045)

367.0(301.0-433.0)

<0.0001

T-tau (pg/ml), median (IQR)

239.5(196.3-279.0)

596.0(455.0-858.5)

<0.0001

P-tau181 (pg/ml), median (IQR)

45.0(36.8-58.3)

95.0(75.0-111.5)

<0.0001

T-tau/Aβ1-42 ratio, median (IQR)

0.25(0.19-0.33)

1.56(1.24-2.55)

<0.0001

sTREM2 (pg/ml), median (IQR)

195.6(131.0-240.7)

231.2(172.5-305.4)

0.0457

  1. Data expressed as mean ± SD or median (IQR) as appropriate. Probability values (p) denote differences between control and AD. A χ2 test was used for gender and APOE genotype comparisons. CSF biomarkers and sTREM2 were evaluated using the Mann-Whitney U test